The International Association for the Study of Lung Cancer (IASLC) shared a post on X:
“HT25: Tokyo is where science meets impact!
- Molecular and immune drivers of early lung cancer
- Biomarkers and AI diagnostics
- Translational science to clinical care
- Emerging therapies to intercept disease
Join the conversation this November.”
More posts featuring IASLC.